| Identification | Back Directory | [Name]
Edratide | [CAS]
433922-67-9 | [Synonyms]
Edratide
EDRATIDUM
Edratide [inn]
Unii-38plp07bkc
Edratide Acetate
Glycyl-L-tyrosyl-L-tyrosyl-L-tryptophyl-L-seryl-L-tryptophyl-L-isoleucyl-L-arginyl-L-glutaminyl-L-prolyl-L-prolylglycyl-L-lysylglycyl-L-glutamyl-L-glutamyl-L-tryptophyl-L-isoleucylglycine
Glycine, glycyl-L-tyrosyl-L-tyrosyl-L-tryptophyl-L-seryl-L-tryptophyl-L-isoleucyl-L-arginyl-L-glutaminyl-L-prolyl-L-prolylglycyl-L-lysylglycyl-L-α-glutamyl-L-α-glutamyl-L-tryptophyl-L-isoleucyl- | [Molecular Formula]
C111H149N27O28 | [MDL Number]
MFCD09837940 | [MOL File]
433922-67-9.mol | [Molecular Weight]
2309.53 |
| Chemical Properties | Back Directory | [density ]
1.50±0.1 g/cm3(Predicted) | [form ]
Solid | [color ]
White to off-white | [Sequence]
Gly-Tyr-Tyr-Trp-Ser-Trp-Ile-Arg-Gln-Pro-Pro-Gly-Lys-Gly-Glu-Glu-Trp-Ile-Gly |
| Hazard Information | Back Directory | [Uses]
Treatment of systemic lupus erythematosus. | [in vivo]
Edratide (20-50 μg; s.c.; once a week for 10 weeks) exerts beneficial effects on SLE is through regulation of gene expression[2].
Edratide (50 μg/mouse; s.c.; 10 weekly) reduces the rates of apoptosis and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL in SLE mouse[3]. | Animal Model: | 6-7 months female mice (with established SLE)[2] | | Dosage: | 20-50 μg | | Administration: | Subcutaneously injection; once a week for 10 weeks | | Result: | Up-regulated the RNA transcripts of Tnfsf4, Il5ra, Zbtb20, Nid1, down-regulated the transcripts of Tfpi and S100a8. |
| Animal Model: | 7-8 months SLE-afflicted BWF1 female mice[3] | | Dosage: | 50 μg/mouse | | Administration: | S.c.; 10 weekly | | Result: | Reduced apoptosis, down-regulated caspase-8 and caspase-3, and up-regulated Bcl-xL. |
|
|
|